These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 18358555)

  • 1. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients.
    Ersoy C; Kiyici S; Budak F; Oral B; Guclu M; Duran C; Selimoglu H; Erturk E; Tuncel E; Imamoglu S
    Diabetes Res Clin Pract; 2008 Jul; 81(1):56-60. PubMed ID: 18358555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
    Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of metformin and diet on plasma testosterone and leptin levels in obese men.
    Ozata M; Oktenli C; Bingol N; Ozdemir IC
    Obes Res; 2001 Nov; 9(11):662-7. PubMed ID: 11707532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30.
    Glueck CJ; Fontaine RN; Wang P; Subbiah MT; Weber K; Illig E; Streicher P; Sieve-Smith L; Tracy TM; Lang JE; McCullough P
    Metabolism; 2001 Jul; 50(7):856-61. PubMed ID: 11436194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
    J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients.
    Kiyici S; Ersoy C; Kaderli A; Fazlioglu M; Budak F; Duran C; Gul OO; Sigirli D; Baran I; Tuncel E; Erturk E; Imamoglu S
    Diabetes Res Clin Pract; 2009 Oct; 86(1):44-50. PubMed ID: 19674806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance.
    de Aguiar LG; Bahia LR; Villela N; Laflor C; Sicuro F; Wiernsperger N; Bottino D; Bouskela E
    Diabetes Care; 2006 May; 29(5):1083-9. PubMed ID: 16644641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of metformin on fibrinogen levels in obese patients with type 2 diabetes.
    Fanghänel G; Silva U; Sanchez-Reyes L; Sisson D; Sotres D; Torres EM
    Rev Invest Clin; 1998; 50(5):389-94. PubMed ID: 9949668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The metabolic effects of once daily extended-release metformin in patients with type 2 diabetes: a multicentre study.
    Gao H; Xiao W; Wang C; Zhang J; Yang Y; Yang J; Yang W; Hong T
    Int J Clin Pract; 2008 May; 62(5):695-700. PubMed ID: 18412932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term effects of metformin in type 2 diabetes.
    Eriksson A; Attvall S; Bonnier M; Eriksson JW; Rosander B; Karlsson FA
    Diabetes Obes Metab; 2007 Jul; 9(4):483-9. PubMed ID: 17587390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects--the Carmos study.
    Andreadis EA; Katsanou PM; Georgiopoulos DX; Tsourous GI; Yfanti GK; Gouveri ET; Diamantopoulos EJ
    Exp Clin Endocrinol Diabetes; 2009 Apr; 117(4):175-80. PubMed ID: 19053032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of short-term glycemic regulation with gliclazide and metformin on postprandial lipemia.
    Emral R; Köseoğlulari O; Tonyukuk V; Uysal AR; Kamel N; Corapçioğlu D
    Exp Clin Endocrinol Diabetes; 2005 Feb; 113(2):80-4. PubMed ID: 15772898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of a long-term oral L-arginine treatment added to a hypocaloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patients.
    Lucotti P; Setola E; Monti LD; Galluccio E; Costa S; Sandoli EP; Fermo I; Rabaiotti G; Gatti R; Piatti P
    Am J Physiol Endocrinol Metab; 2006 Nov; 291(5):E906-12. PubMed ID: 16772327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients.
    Rigla M; Wägner AM; Borrell M; Mateo J; Foncuberta J; de Leiva A; Ordóñez-Llanos J; Pérez A
    Metabolism; 2006 Nov; 55(11):1437-42. PubMed ID: 17046544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total and acylated ghrelin levels in type 2 diabetic patients: similar levels observed after treatment with metformin, pioglitazone or diet therapy.
    Kiyici S; Ersoy C; Oz Gul O; Sarandol E; Demirci M; Tuncel E; Sigirli D; Erturk E; Imamoglu S
    Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):386-90. PubMed ID: 19629933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin in the treatment of obesity in subjects with normal glucose tolerance.
    Tankova T; Dakovska L; Kirilov G; Koev D
    Rom J Intern Med; 2003; 41(3):269-75. PubMed ID: 15526510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes.
    Wagner H; Degerblad M; Thorell A; Nygren J; Ståhle A; Kuhl J; Brismar TB; Ohrvik J; Efendic S; Båvenholm PN
    Diabetes Care; 2006 Jul; 29(7):1471-7. PubMed ID: 16801564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An exercise intervention without weight loss decreases circulating interleukin-6 in lean and obese men with and without type 2 diabetes mellitus.
    Dekker MJ; Lee S; Hudson R; Kilpatrick K; Graham TE; Ross R; Robinson LE
    Metabolism; 2007 Mar; 56(3):332-8. PubMed ID: 17292721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.